Product Images Pregabalin

Percent of Patients Improved with an unclear heading and unreadable text. Therefore, the description cannot be generated.*

The text appears to be a table or a chart showing different responder rates (%), followed by some numeric values. However, the table/chart does not present enough information to identify what is being measured or evaluated. In this context, it is not possible to provide a useful description of the text.*

This text provides information on dosage and storage for Pregabalin capsules. It advises storing the capsules at a temperature of 25°C (77°F) and allowing excursions between 15-30°C (59-86°F). The capsules must be dispensed in child-resistant containers and should not be used if the safety foil seal is broken or missing. The text instructs to see the accompanying prescribing information for dosage and usage details. The manufacturing company and address are also provided, along with the medication guide to be given with each prescription.*

This is a description of prescription medicine called Pregabalin. Each capsule contains 150 mg of Pregabalin and should be kept in tight, child-resistant containers at 25°C (77°F) with slight temperature excursions permitted. The medicine is manufactured by two different companies, Time-Cap Labs, Inc. in New York and Marksans Pharma Ltd. in India. The product NDC number is 25000-183-07. The accompanying prescribing information and medication guide should be given to each patient. The storage should not be used if the inner safety foil seal is broken or missing.*

This is a medication called Pregabalin EV Capsules that are dispensed in tight, child-resistant containers. Each capsule contains 200 mg pregabalin. The storage temperature is 25 degrees Celsius with permitted excursions to 15-30 degrees Celsius. The medication should not be used if the inner safety foil seal is broken or missing. The prescribing information should be consulted for dosage and use. The medication guide should be given to each patient, and it is available only with a prescription. The manufacturer is Marksans Pharma Ltd located in Goa, India and it is manufactured by Time-Cap Labs, Inc. located in Farmingdale, NY, USA.*

This text provides storage instructions, precautions and dosage of pregabalin capsules containing 225mg, manufactured by Marksans Pharma Ltd. for Time-Cap Labs, Inc. The capsules should be stored at 25°C with permissible excursions of 15-30°C and dispensed in a tight child-resistant container. The medication guide enclosed should be given to each patient. The prescribing information is not available in this text.*

This is a medication guide with dosage and storage information for Pregabalin capsules containing 25mg of the active ingredient. The capsules should be stored between 15-30°C (59-86°F) and in tight, child-resistant containers, and should not be used if the safety foil seal is broken or missing. The medication is manufactured by Marksans Pharma Ltd. in India and distributed by Time-Cap Labs, Inc. in Farmingdale, NY, USA. The guide recommends dispensing an accompanying medication guide to each patient.*

This text provides instructions and information about storage, dispensing, dosage, and manufacturing of pregabalin capsules. The recommended storage temperature range is between 15-30°C (59-86°F) and the capsules should be dispensed in tight, child-resistant containers. It also indicates that the medication guide should be dispensed to each patient and that the dosage and use should be based on the accompanying prescribing information. The text includes details about the manufacturer, Time-Cap Labs, Inc. and Marksans Pharma Ltd., as well as the NDC number and the number of capsules in each package.*

This is a medication guide for Pregabalin EV Capsules containing 50mg pregabalin. The medicine should be stored at 25°C with some allowances for temperature excursions. It should not be used if the foil seal is missing or broken, and it is advised to dispense it in tight, child-resistant containers. The prescribing information should be checked before use. The capsule is manufactured by Marksans Pharma Ltd in Verna, Goa, and distributed by Time-Cap Labs, Inc in Farmingdale, NY. Dispensing the accompanying medication guide to each patient is advisable.*

This is a report that includes various types of disorders and conditions that can be caused by a placebo based on a study. The report includes percentages of participants experiencing these disorders/conditions under certain System Organ Class such as Eye disorders, Gastrointestinal disorders, Nervous system disorders, among others. Some examples of the disorders/conditions are blurred vision, dry mouth, constipation, muscular weakness, somnolence, hypertension, and hypotension.*

Daily Dose of Pregabalin was evaluated as a treatment for reducing seizures in patients in multiple studies. The dosing regimen started at baseline seizure levels and increased up to 600mg/day. The results showed a significant reduction in seizures for patients who received Pregabalin compared to those on Placebo. However, the text contains errors and inconsistencies which makes the interpretation of the actual results unclear.*

The text is presenting data on patients' global impression of change in different treatment groups in terms of their improvements or placebos, measured by a certain unit (mg/day). However, further information or context is not available, such as what the abbreviations stand for or what condition the patients were treated for.*

This appears to be a medical document with a list of body systems, preferred terms, and related medical conditions. It seems to be a chart displaying the incidence of various medical conditions among a testing population, with N values to indicate the number of people tested. However, the formatting is inconsistent and the text is partially illegible, making it difficult to interpret accurately.*

This text is a medical report that includes various symptoms suffered by a patient. The report categorizes the symptoms in different body systems such as Accidental Injury, Digestive, Metabolic and Nutritional Disorders, Nervous System, and Special Senses. However, due to the large amount of errors and missing information, it is difficult to interpret the specific details of the patient's condition.*

This appears to be an extract from a medical report, listing a range of disorders and symptoms experienced by a patient. The report cites various medications and dosages used to treat these issues. However, due to inconsistencies and missing information in the text, it is difficult to understand the full context of the report.*

This text is a table presenting data related to the effect of Pregabalin on seizure frequency. The table has three columns, including the type of treatment (Placebo, 2.5 mg/kg/day, and 10 mg/kg/day), the number of patients (N), and the median baseline seizure frequency. The data also shows the median percent change in seizure frequency after the treatment and the relative difference compared to placebo. The results show that both doses of Pregabalin have a significant effect in reducing seizure frequency compared to placebo.*